Banarian Nordic Res (BVNKF) 21.1500 $BVNKF
Bavarian Nordic to Host First Quarter 2014 Results Conference Call
Thomson Reuters ONE - Tue May 06, 10:31AM CDT
KVISTGAARD, Denmark - May 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 first quarterly results on Wednesday, May 14, 2014.
Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 in Bladder Cancer
GlobeNewswire - Mon Apr 28, 1:55AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer.
Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the Board
Thomson Reuters ONE - Thu Apr 24, 12:55PM CDT
KVISTGAARD, Denmark, April 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that following the ordinary general meeting, the board has elected Gerard van Odijk, M.D. as new chairman of the board of Bavarian Nordic. He succeeds Asger Aamund who has served as chairman since 1994. Furthermore Anders Gersel Pedersen, M.D. has been elected deputy chairman of the board.
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 24 April 2014
Thomson Reuters ONE - Thu Apr 24, 12:55PM CDT
KVISTGARD, Denmark - April 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows:
Bavarian Nordic Announces Activities Around the 2014 ASCO Annual Meeting
Thomson Reuters ONE - Wed Apr 23, 12:49AM CDT
KVISTGAARD, Denmark, April 23, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the company will be present at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June 3.
Bavarian Nordic Announces Execution of Option on Freeze-Dried IMVAMUNE
GlobeNewswire - Tue Apr 22, 12:53AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised an option at a value of USD 21.9 million under the existing development contract for freeze-dried IMVAMUNE smallpox vaccine. This will fund the transfer of the already validated manufacturing process to a commercial manufacturing line with a larger capacity.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Bavarian Nordic Presents Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated data from an NCI sponsored combination study of Bavarian Nordic's active immunotherapy candidate PROSTVAC and ipilimumab will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Wednesday, April 9, 2014. The data highlights the potential synergy of combining PROSTVAC with an immune checkpoint inhibitor.
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on
Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.
Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.
Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.
Bavarian Nordic to Present at the 16th Annual BIO CEO & Investor Conference in New York City
Thomson Reuters ONE - Fri Feb 07, 10:30AM CST
KVISTGAARD, Denmark - February 7, 2014 - Bavarian Nordic (OMX: BAVA, OTC: BVNRY) announced today that James Breitmeyer, MD, PhD and Executive Vice President will present at the 16th Annual BIO CEO & Investor Conference in New York City on Monday, February 10, 2014 at 4:30 p.m. ET.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine
GlobeNewswire - Fri Nov 22, 12:52AM CST
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Health Canada has granted a Notice of Compliance approving IMVAMUNE(R) for active immunization against smallpox in a public health emergency. IMVAMUNE is indicated for persons 18 years of age and older who are contraindicated to replicating smallpox vaccines. This includes individuals with immune deficiencies and skin disorders.
Bavarian Nordic to Host First Quarter 2014 Results Conference Call
Thomson Reuters ONE - Tue May 06, 10:31AM CDT
KVISTGAARD, Denmark - May 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 first quarterly results on Wednesday, May 14, 2014.
Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 in Bladder Cancer
GlobeNewswire - Mon Apr 28, 1:55AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer.
Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the Board
Thomson Reuters ONE - Thu Apr 24, 12:55PM CDT
KVISTGAARD, Denmark, April 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that following the ordinary general meeting, the board has elected Gerard van Odijk, M.D. as new chairman of the board of Bavarian Nordic. He succeeds Asger Aamund who has served as chairman since 1994. Furthermore Anders Gersel Pedersen, M.D. has been elected deputy chairman of the board.
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 24 April 2014
Thomson Reuters ONE - Thu Apr 24, 12:55PM CDT
KVISTGARD, Denmark - April 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows:
Bavarian Nordic Announces Activities Around the 2014 ASCO Annual Meeting
Thomson Reuters ONE - Wed Apr 23, 12:49AM CDT
KVISTGAARD, Denmark, April 23, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the company will be present at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June 3.
Bavarian Nordic Announces Execution of Option on Freeze-Dried IMVAMUNE
GlobeNewswire - Tue Apr 22, 12:53AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised an option at a value of USD 21.9 million under the existing development contract for freeze-dried IMVAMUNE smallpox vaccine. This will fund the transfer of the already validated manufacturing process to a commercial manufacturing line with a larger capacity.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Bavarian Nordic Presents Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated data from an NCI sponsored combination study of Bavarian Nordic's active immunotherapy candidate PROSTVAC and ipilimumab will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Wednesday, April 9, 2014. The data highlights the potential synergy of combining PROSTVAC with an immune checkpoint inhibitor.
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on
Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.
Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.
Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.
Bavarian Nordic to Present at the 16th Annual BIO CEO & Investor Conference in New York City
Thomson Reuters ONE - Fri Feb 07, 10:30AM CST
KVISTGAARD, Denmark - February 7, 2014 - Bavarian Nordic (OMX: BAVA, OTC: BVNRY) announced today that James Breitmeyer, MD, PhD and Executive Vice President will present at the 16th Annual BIO CEO & Investor Conference in New York City on Monday, February 10, 2014 at 4:30 p.m. ET.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine
GlobeNewswire - Fri Nov 22, 12:52AM CST
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Health Canada has granted a Notice of Compliance approving IMVAMUNE(R) for active immunization against smallpox in a public health emergency. IMVAMUNE is indicated for persons 18 years of age and older who are contraindicated to replicating smallpox vaccines. This includes individuals with immune deficiencies and skin disorders.
